Crowdsourcing Management of Complex Pediatric Dermatology Cases: Focus on RIME

Conclusions

• RIME is presented as a predominantly mucosal, post-infectious eruption in children that is often preceded by fever, cough, sore throat, and malaise.
• Because erosive mucositis has a broad differential, initial evaluation should consider infectious triggers, drug reactions, autoimmune blistering disease, and other inflammatory causes.
• Mycoplasma pneumoniae is an important and common trigger for RIME, but the syndrome can also follow other respiratory and viral infections, so broader infectious testing is often reasonable.
• Identifying the infectious trigger may help confirm the diagnosis, but treating that infection alone does not appear to reliably alter the course of the mucocutaneous disease.
• Supportive inpatient care is essential, including attention to hydration, nutrition, pain control, oral hygiene, and early specialty consultation for eyes, genital involvement, pharyngeal disease, or airway risk.
• Most experts still use systemic anti-inflammatory therapy early, with corticosteroids, etanercept, cyclosporine, and sometimes IVIG all considered, but practice is shifting toward TNF-alpha blockade in some centers.
• Etanercept appears promising because it can produce rapid symptom improvement and may shorten hospitalization when given early, although relapses can still occur and some patients require additional treatment.
• Early treatment matters because the full severity of mucositis may not be apparent on day 1, and delays can miss the window to meaningfully shorten the disease course and hospital stay.
• The overall prognosis of RIME is generally good with very low mortality, but morbidity can be substantial because patients may require prolonged hospitalization and can develop ocular or mucosal sequelae.
• The presentation suggests that pediatric dermatology management of RIME should move toward more standardized, outcomes-based treatment documentation to better compare therapies and improve care.